Anixa Biosciences is trading at $3.46 (+6.46%) in after-hours trading, with the move appearing speculative or liquidity-driven and no definitive catalyst identified.
- No major company-specific announcement dated August 10, 2026 was identified.
- The latest listed company release was July 14, 2026, concerning Australian patent acceptance for breast-cancer vaccine technology.
- Broad markets were largely flat to modestly lower, so macro sentiment does not clearly explain the move.